Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Yoo YW, Cha SW, Kim A, Na SY, Lee YW, Kim SH, Lee HIe, Lee YJ, Yang HW, Jung SH.

Gut Liver. 2012 Apr;6(2):256-61. doi: 10.5009/gnl.2012.6.2.256.

2.

Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.

Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX.

Chin Med J (Engl). 2010 Sep;123(18):2600-6.

3.

Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.

Ueki T, Otani K, Kawamoto K, Shimizu A, Fujimura N, Sakaguchi S, Matsui T.

J Gastroenterol. 2007 Feb;42(2):161-7.

PMID:
17351806
4.

Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.

Park JY, Jeon TJ, Hwang MW, Sinn DH, Oh TH, Shin WC, Choi WC.

Pancreatology. 2014 Jul-Aug;14(4):263-7. doi: 10.1016/j.pan.2014.03.022.

PMID:
25062874
5.

Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.

Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, Suetsugu H, Kawashima K, Komazawa Y, Ishimura N, Ishihara S, Amano Y, Kinoshita Y.

J Gastroenterol Hepatol. 2006 Jun;21(6):1065-9.

PMID:
16724996
6.

Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update.

Zheng MH, Bai JL, Meng MB, Chen YP.

Curr Ther Res Clin Exp. 2008 Aug;69(4):288-304. doi: 10.1016/j.curtheres.2008.08.001.

7.

Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.

Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zeng Q.

BMC Gastroenterol. 2007 Feb 12;7:6.

8.

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate.

Chang JH, Lee IS, Kim HK, Cho YK, Park JM, Kim SW, Choi MG, Chung IS.

Gut Liver. 2009 Sep;3(3):205-10. doi: 10.5009/gnl.2009.3.3.205.

9.

Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.

Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB.

Gastrointest Endosc. 2007 Jun;65(7):982-7.

PMID:
17531632
10.

Antiproteases in preventing post-ERCP acute pancreatitis.

Tsujino T, Kawabe T, Omata M.

JOP. 2007 Jul 9;8(4 Suppl):509-17. Review.

11.

Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp?

Chen S, Shi H, Zou X, Luo H.

Pancreas. 2010 Nov;39(8):1231-7. doi: 10.1097/MPA.0b013e3181dc67e7.

PMID:
20531245
12.

Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.

Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, Spirito F, Silla M, Forte G, Terruzzi V, Marenco G, Ciliberto E, Sabatino A, Monica F, Magnolia MR, Perri F.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):713-8.

PMID:
15290665
13.
14.

Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.

Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, Ito Y, Nakai Y, Tada M, Matsumura M, Yoshida H, Kawabe T, Shiratori Y, Omata M.

Clin Gastroenterol Hepatol. 2005 Apr;3(4):376-83.

PMID:
15822043
15.

Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.

Yoo JW, Ryu JK, Lee SH, Woo SM, Park JK, Yoon WJ, Lee JK, Lee KH, Hwang JH, Kim YT, Yoon YB.

Pancreas. 2008 Nov;37(4):366-70. doi: 10.1097/MPA.0b013e31817f528f.

PMID:
18953247
16.

The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Tsujino T, Isayama H, Nakai Y, Ito Y, Togawa O, Toda N, Arizumi T, Kogure H, Yamamoto K, Mizuno S, Yashima Y, Yagioka H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Sasahira N, Tada M, Koike K.

J Gastroenterol. 2013 Aug;48(8):982-8. doi: 10.1007/s00535-012-0698-5.

PMID:
23090004
17.

Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.

Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V.

Gastrointest Endosc. 2007 Apr;65(4):624-32.

PMID:
17383459
19.

[Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].

Kwon YH, Kim JY, Lee SJ, Jang SY, Park HW, Yang HM, Jung MK, Jeon SW, Cho CM, Tak WY, Kweon YO, Kim SK.

Korean J Gastroenterol. 2012 Mar;59(3):232-8. Korean.

20.

Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.

Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, Leandro G, Leo P, De Maio G, Perri F.

Gastrointest Endosc. 2002 Oct;56(4):488-95.

PMID:
12297762

Supplemental Content

Support Center